ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
ACCELERATING LIFE SCIENCE INNOVATION
Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs.
“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Concentrating on cell therapy treatments for serious diseases with high, unmet needs with an initial focus on the eye, including geographic atrophy age-related macular degeneration and advanced retinitis pigmentosa.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and to advance in vivo candidate for [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive biology company pioneering evolution-based design of proteins, founded [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex [...]
